恶性肿瘤靶向治疗.ppt

S-1用法 体表面积＜1.25 m2，40 mg/次。 体表面积1.25～1.50 m2， 50 mg/次。 体表面积＞1.50 m2， 60 mg/次。 最大剂量：75 mg/次，常用80 ～150 mg/d,Bid 力比泰独特的多靶点作用机制[1]： Reference:1. Shin C, et al. Cancer Res. 1997; 57: 1116-1123. 多靶点抗肿瘤，显著延长生命 同时高效抑制三个叶酸依赖性酶 力比泰与其他抗叶酸药物比较：三靶点协同抑制作用 % [CI=5.9,13.2] [CI=5.7,12.8] NSCLC – Second LineDocetaxel vs. ALIMTA – Responses Hanna et al, J Clin Oncol: 22:1589-97, 2004 0.00 0.25 0.50 0.75 1.00 0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 Months ALIMTA (n=283) Docetaxel (n=288) % Progression MPFS = 2.9 mos MPFS = 2.9 mos ITT = intent to treat HR = hazard ratio CI = confidence interval MPFS = median progression-free survival HR 0.97 95% CI of HR (0.82, 1.16) NSCLC – Second LineDocetaxel vs. ALIMTA – DFS Hanna et al, J Clin Oncol: 22:1589-97, 2004 ALIMTA (n=283) Docetaxel (n=288) Survoival Months 0.00 0.25 0.50 0.75 1.00 0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 MST 8.3 m 1-year: 29.7% HR 0.99 95% CI of HR (0.82-1.20) MST 7.9 m 1-year: 29.7% NSCLC – Second LineDocetaxel vs. ALIMTA – Overall Survival (ITT) Hanna et al, J Clin Oncol: 22:1589-97, 2004 ALIMTA Docetaxel (n=265) (n=276) p Neutropenia 5.3 40.2 .001 Febrile Neutropenia 1.9 12.7 .001 Infection w/ G3-4 Neutropeni 0 3.3 0.004 ALT elevatio 1.9 0.0 0.028 Alopecia (all grades) 6.4 37.7 .001 Hanna et al, J Clin Oncol: 22:1589-97, 2004 NSCLC – Second LineDocetaxel vs. ALIMTA – Toxicity * * Significant CTC G3-4 Toxicity Differences 谢 谢 * 见幻灯片描述 CD117是GIST的特定诊断标志 * C-kit是一种细胞膜受体络氨酸激酶，在细胞膜外区和内区均有一些特定的位点。外